1. Home
  2. ADSK vs ALNY Comparison

ADSK vs ALNY Comparison

Compare ADSK & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Autodesk Inc.

ADSK

Autodesk Inc.

N/A

Current Price

$239.39

Market Cap

52.3B

Sector

Technology

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$307.23

Market Cap

42.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADSK
ALNY
Founded
1982
2002
Country
United States
United States
Employees
N/A
115
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.3B
42.1B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
ADSK
ALNY
Price
$239.39
$307.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
26
29
Target Price
$338.88
$467.68
AVG Volume (30 Days)
1.8M
913.6K
Earning Date
02-26-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
2.15
206.88
EPS
5.23
2.33
Revenue
$7,206,000,000.00
$1,037,418,000.00
Revenue This Year
$15.10
$53.50
Revenue Next Year
$10.33
$32.29
P/E Ratio
$47.35
$134.28
Revenue Growth
17.53
22.88
52 Week Low
$215.01
$205.87
52 Week High
$329.09
$495.55

Technical Indicators

Market Signals
Indicator
ADSK
ALNY
Relative Strength Index (RSI) 40.87 35.87
Support Level $215.51 $296.91
Resistance Level $262.07 $310.00
Average True Range (ATR) 6.31 9.36
MACD -0.64 -0.12
Stochastic Oscillator 7.68 26.55

Price Performance

Historical Comparison
ADSK
ALNY

About ADSK Autodesk Inc.

Founded in 1982, Autodesk is a multinational software company best known for pioneering computer-aided design, or CAD, with its AutoCAD product. Nowadays, Autodesk provides design software for a variety of verticals, including architecture & construction, manufacturing, and media & entertainment. Autodesk products have been used in some of the world's most iconic landmarks, like Burj Khalifa, and well-known movie titles like Avatar.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: